Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

"Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers" was originally created and published by Pharmaceutical ...

In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or ...

Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.